Samsung Biologics' $1.81B Peptide CDMO Bet: Manufacturing Capacity Play, Not a Drug Asset

Swiss CDMOs and CROs Experience New Growth Wave

The Swiss CDMO and CRO sector is experiencing a significant boom, driven by increasing global demand for specialized manufacturing, advanced preclinical models, and complex clinical trials. This growth is underscored by recent M&A activities, such as Samsung Biologics' CHF 1.46 billion ($1.81 billion) all-cash tender offer for peptide CDMO PolyPeptide Group, aimed at entering the thriving obesity and metabolic drug market, and Corden Pharma's acquisition of AmbioPharm. Switzerland's robust life sciences ecosystem, strong talent pool, and efficient regulatory framework position it as a key global hub for drug development services, attracting international sponsors and fostering innovation in areas like decentralized trials and AI integration.

• Strategic M&A and Market Expansion: The Swiss CDMO and CRO landscape is marked by significant consolidation, exemplified by Samsung Biologics' CHF 1.46 billion ($1.81 billion) all-cash bid for PolyPeptide Group, signaling a strategic move into the high-demand obesity and metabolic drug market, particularly for GLP-1s. This trend, also seen with Corden Pharma's acquisition of AmbioPharm, highlights the industry's response to the surging global appetite for specialized manufacturing capabilities, especially in peptides.
• Switzerland's Global Hub Status: Switzerland maintains a critical role in the global drug development supply chain, excelling in high-end modalities, advanced therapies, peptides, and biologics. The country's appeal to international sponsors is bolstered by its strong talent base, innovative environment, and a rigorous yet efficient regulatory framework overseen by Swissmedic and the Human Research Act. With approximately 1,200 active clinical trials and 45% of CRO services exported, Switzerland is a preferred partner for international collaborations.
• Innovation in Clinical Trials and Technology: Swiss CROs are at the forefront of adopting advanced methodologies, including decentralized and hybrid clinical trials, to enhance patient accessibility and reduce burden. There's a growing demand for sophisticated human-relevant models, such as organoids, integrated with immune components and advanced imaging. Furthermore, AI is increasingly being leveraged to improve predictive biology, identify trends earlier, standardize processes, and enhance efficiency and predictability in preclinical research and clinical trial management.

The Evolving Obesity and Metabolic Treatment Landscape

The past five years have witnessed a marked shift in the pharmacological management of obesity and metabolic disorders, driven largely by robust randomized controlled trial data on incretin-based therapies. GLP-1 receptor agonists — particularly subcutaneous semaglutide 2.4 mg — have established a new efficacy benchmark, with meta-analyses of nondiabetic adults demonstrating a mean percentage body weight reduction of -11.85% (95% CI: -12.81 to -10.90) versus placebo. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has pushed that ceiling further, with meta-analysis data in overweight or obese nondiabetic individuals showing a mean body weight change of -16.32% (95% CI: -18.35 to -14.29) versus placebo, alongside significant reductions in BMI (-5.89 kg/m²) and waist circumference (-12.31 cm). Post hoc analyses of the SURMOUNT-1, -3, and -4 trials further demonstrated that tirzepatide maintained clinically meaningful weight reduction even among participants concurrently using weight-inducing medications, with percentage weight changes versus placebo ranging from -13.3% (5 mg) to -21.3% (15 mg) in SURMOUNT-1 — findings that substantially broaden the real-world applicability of this agent.

Beyond weight reduction, the field has evolved to recognize cardiorenal risk modification as a primary therapeutic objective. The SELECT trial established that semaglutide 2.4 mg reduced three-point major adverse cardiovascular events (MACE) by 20% versus placebo in people with overweight or obesity and established atherosclerotic cardiovascular disease but without diabetes — a benefit shown to be consistent irrespective of baseline HbA1c or change in HbA1c, suggesting mechanisms independent of glycemic improvement. The FLOW trial demonstrated that semaglutide reduced major kidney disease events and death from cardiovascular or kidney causes in patients with chronic kidney disease and type 2 diabetes, while the SOUL cardiovascular outcome trial showed that oral semaglutide reduced three-point MACE versus placebo in type 2 diabetes with atherosclerotic cardiovascular disease and/or chronic kidney disease. In head-to-head comparison, tirzepatide was non-inferior to dulaglutide on MACE while achieving greater reductions in weight and HbA1c, reinforcing the cardiometabolic breadth of dual agonism. Regulatory milestones have followed the evidence, including the 2025 Central Drugs Standard Control Organization (CDSCO) approval of semaglutide 2.4 mg in India, positioning it as the first anti-obesity medication with proven cardiovascular benefit in people with obesity without type 2 diabetes.

The landscape has also expanded to address durability, tolerability, and emerging therapeutic targets. Real-world follow-up data from SURMOUNT-CN showed that tirzepatide cessation after 52 weeks led to mean body weight regain of 9.1% and 12.3% in the 10 mg and 15 mg groups respectively over the subsequent 26 weeks, though net weight losses from baseline remained substantial (-8.7% and -10.6%), with residual improvements in cardiometabolic indicators persisting at Week 78. On the safety front, gastrointestinal adverse events — nausea, vomiting, diarrhea, and constipation — remain the predominant tolerability challenge across GLP-1 receptor agonists, with tirzepatide meta-analysis data reporting relative risks of 3.11, 5.94, 2.92, and 2.85 for these events respectively versus placebo, and treatment discontinuation due to adverse events reaching a relative risk of 2.29. Emerging agents including retatrutide, orforglipron, and the GLP-1/GCGR dual agonist mazdutide — the latter demonstrating an 18.89% BMI reduction and 37.00% uric acid reduction in a pediatric case — signal continued pipeline diversification. Collectively, these data reflect a paradigm in which obesity pharmacotherapy is no longer evaluated solely on weight endpoints, but on its capacity to modify downstream cardiorenal and metabolic risk across increasingly heterogeneous patient populations.

Key Unmet Needs Driving Innovation in Obesity and Metabolic Disorders

The landscape of obesity and metabolic disorder management has shifted substantially, driven by recognition that existing therapies leave critical gaps across multiple patient populations and disease dimensions. Pharmacological innovation, particularly in incretin-based multi-agonist therapy, is being shaped by these unmet needs, while structural and access challenges continue to limit the reach of emerging treatments.

• Pediatric and adolescent obesity: 1 in 5 children and adolescents in the United States have obesity, and comorbidities associated with youth-onset obesity tend to have a more severe disease progression in youth compared to their adult counterparts with the same obesity-related condition. Metabolism-associated steatotic liver disease (MASLD) has rapidly evolved into the most common liver disease seen in the pediatric population, with a direct association between its treatment and the treatment of pediatric obesity, underscoring the need for age-appropriate, evidence-based interventions in this population.

• MASLD and metabolic dysfunction-associated steatohepatitis (MASH): Beyond glycaemic control and weight reduction, there is a recognised need to address hepatic and inflammatory pathology in patients with metabolic disorders. Agents such as cotadutide and efinopegdutide are being developed specifically to expand indications to MASLD and MASH, reflecting the inadequacy of current standard-of-care options for these conditions.

• Patients requiring deeper and sustained weight loss: Second-generation pharmacotherapies achieve weight loss of 15–25%, approaching that of bariatric surgery, yet long-term weight maintenance remains a challenge. The weight loss plateau observed at approximately 6 months is physiological and cannot be overcome by simply switching to a different weight-loss diet, highlighting the need for durable pharmacological strategies. Tirzepatide (dual GLP-1/GIP receptor agonist) achieves weight loss of up to 22.5% at the highest doses, and triple agonists such as retatrutide and combinations such as Cagrisema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) are under investigation to push efficacy further.

• Tolerability and dose optimisation: Higher-dose regimens that maximise weight loss carry increased gastrointestinal side effects and higher discontinuation rates. In a network meta-analysis of non-diabetic adults with obesity, the highest odds of treatment discontinuation due to adverse events were observed with semaglutide MTD (OR: 7.36; 95% CI: 2.56 to 21.15) and tirzepatide MTD (OR: 5.56; 95% CI: 2.28 to 13.58), identifying tolerability as a key unmet need in achieving optimal therapeutic outcomes.

• Equitable access and underrepresented populations: Cost, accessibility, and the underrepresentation of low- and middle-income countries in major trials persist as significant challenges. Pharmacogenomic variability may also influence therapeutic response, pointing to the need for tailored implementation strategies and more globally inclusive trial designs to ensure incretin-based therapies reach all populations who could benefit.

Navigating the Competitive Landscape of GLP-1 Therapies

Several next-generation agents targeting GLP-1 receptors — alone or in combination with GIP, glucagon, and other receptors — are advancing through clinical trials for type 2 diabetes and obesity. These molecules extend the GLP-1 mechanism by adding complementary receptor targets to achieve synergistic glycemic control, weight reduction, and cardiometabolic benefit. The pipeline spans dual, triple, and novel co-agonist classes, with most candidates developed as long-acting, once-weekly formulations.

Switzerland's Strategic Ascent in Specialized Drug Development

The recent surge in the Swiss CDMO and CRO sector, highlighted by significant M&A activities, underscores a pivotal moment in the global pharmaceutical landscape. This growth is not merely an expansion but a strategic evolution, driven by the imperative to innovate across the drug development continuum.

A key driver is the explosive demand for peptide therapeutics, particularly in the obesity and metabolic disease space. The remarkable efficacy of GLP-1-based therapies, achieving weight loss levels once thought exclusive to bariatric surgery, has created an urgent need for specialized manufacturing. Samsung Biologics' acquisition of PolyPeptide is a clear signal of this strategic imperative, aiming to secure the necessary infrastructure to produce these complex molecules at a global scale. However, this ambition is tempered by the inherent challenges in peptide manufacturing:

• High Process Mass Intensity (PMI): Traditional methods like solid-phase peptide synthesis (SPPS) are resource-intensive, demanding significant solvent and reagent use, which impacts both cost and environmental sustainability. The industry must continue to explore and scale greener alternatives like liquid-phase peptide synthesis (LPPS) to meet future demand responsibly.

Beyond manufacturing, the Swiss ecosystem is embracing cutting-edge technologies to de-risk and accelerate early-stage development. Microphysiological systems (MPS) and Organ-on-a-Chip platforms are gaining traction, promising more human-relevant in vitro models that can improve drug approval rates and reduce reliance on animal testing. While these technologies hold immense potential, their successful translation into routine pharmacological practice requires robust in vitro-in vivo correlation and overcoming commercialization hurdles.

In clinical development, decentralized clinical trials (DCTs) are reshaping how studies are conducted, offering benefits such as improved patient accessibility, diversity, and the collection of more real-world data. Yet, their implementation is not without complexities:

• Operational Challenges: Ensuring robust investigator oversight, maintaining participant safety, managing data quality and IT system integration, and navigating intricate contractual agreements with third-party providers are critical considerations for successful DCT execution.

Overall, Switzerland's robust life sciences infrastructure, skilled workforce, and forward-thinking regulatory environment position it as a crucial hub for these specialized services. The convergence of advanced manufacturing, innovative preclinical tools, and flexible clinical trial designs reflects a strategic adaptation to the evolving demands of modern drug development, aiming to bring life-changing therapies to patients more efficiently and sustainably.